Study

ABI-MS

91f1a748-c48e-11ec-9b1d-acde48001122

Patients with MS or Clinically Isolated Syndrome (CIS) diagnosis according to McDonald criteria and who were prescribed IFN-beta-1a intramuscularly (IM), IFN-beta-1a subcutaneously (SC), or IFN-beta-1b SC (original product or biosimilar) were recruited from January 30, 2014 to January 22, 2016. Patients who were not naive to IFN-beta were excluded.

FAIRplus stamp Export as DATS
Types Observational

Datasets

1
  1. ABIRISK MS clinical and ADA data

Study description
Primary purpose
Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment
Study types
observational
Description of cohorts
147 patients (103 female, 44 male) diagnosed with MS.

Subjects
Organisms
Homo sapiens
Number of subjects
147
Diseases
multiple sclerosis
Sample sources
tissue sample
Samples collected
RNA DNA PBMCs plasma